Tag: firms

NEW YORK and NEW ORLEANS, July 15, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

NEW YORK and NEW ORLEANS, July 15, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in securities class action lawsuits against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between November 3, 2022 and April 30, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the District of New Jersey.

Burlingame, CA, July 15, 2025 (GLOBE NEWSWIRE) -- The global Vitrification Market is estimated to be valued at USD 10.82 Bn in 2025 and is expected to reach USD 31.15 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.3% from 2025 to 2032. The vitrification market is witnessing growing demand due to its expanding applications in biobanking, assisted reproductive technologies, and cryopreservation of oocytes, embryos, and stem cells. This technique offers faster cooling rates and higher cell survival compared to conventional freezing, making it increasingly preferred in fertility clinics and research institutions. Market growth is also driven by advancements in cryoprotectant solutions and rising awareness of fertility preservation. Opportunities lie in emerging markets, technological innovations, and collaborations between biotech firms and healthcare providers to improve storage protocols and expand access to vitrification services.

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of the SmarTest® Patch to its portfolio of non-invasive drug testing solutions. The SmarTest Patch is an innovative wearable device, developed by SMARTOX®, that enables continuous drug detection through sweat over a 7 to 10-day period. The SmarTest Patch complements the Company's flagship product, the Intelligent Fingerprinting Drug Testing Solution, strengthening its product portfolio of sweat-based, non-invasive testing technologies.

Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. He takes over from Ruth McKernan, who retains her role on the Board as a Director and Interim Chief Executive Officer (CEO).